Treatment of Early Trilogy Valve Aortic Insufficiency With Valve-in-Valve Transcatheter Aortic Valve Replacement.

Aortic insufficiency (AI) is the third most common left valvular heart disease. Transcatheter aortic valve replacement (TAVR) is becoming popular in the treatment of AI. The Trilogy Valve (JenaValve Technology, Irvine, California, United States) is in clinical trials. We report here a case of valve-in-valve TAVR with a Sapien S3 Ultra Resilia valve (Edwards Lifesciences Corporation, Irvine, California, United States) for recurrent AI after Trilogy valve placement.